SRPT Sarepta Therapeutics, Inc.

Price Chart

Executive Summary

Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive Plan (authorizing up to 6,286,841 shares for issuance) and the 2026 Employee Stock Purchase Plan (1,500,000 shares), replacing prior plans. All director nominees were elected, and KPMG was ratified as auditor. This is a routine governance filing with no material financial impact.

Actionable Insight

Key Facts

• Stockholders approved the 2026 Equity Incentive Plan, authorizing up to 6,286,841 shares of common stock for issuance under awards.
• Stockholders approved the 2026 Employee Stock Purchase Plan, authorizing up to 1,500,000 shares of common stock for purchase by employees.
• All five director nominees were elected: Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly.
• Advisory vote on named executive officer compensation for 2025 was approved (45,185,398 For, 22,373,065 Against).
• KPMG LLP was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026 (79,907,368 For, 2,110,136 Against).
• Record date for the meeting was April 8, 2026, with 105,571,146 shares outstanding; 77.97% quorum achieved.

Financial Impact

No financial figures reported. The equity plan authorizes up to 6,286,841 shares (approximately 6.0% of outstanding shares) for future equity compensation, and the ESPP authorizes up to 1,500,000 shares (approximately 1.4% of outstanding) for employee stock purchases at a 15% discount.

Risk Factors

• Potential dilution from future equity awards under the 2026 Plan (up to ~6% of outstanding shares).
• Advisory say-on-pay vote showed 33% opposition (22.4M against), indicating some shareholder dissatisfaction with executive compensation.

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status